Abstract: Described herein, inter alia, are certain substituted piperazines, for example, having the Formula 182, and pharmaceutical compositions for the treatment and prevention of diseases related to the formation of A?42 oligomers in a subject. It further provides a method of reducing formation of or disrupting A?42 oligomers in a subject, the method comprising the step of administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition.
Abstract: The present disclosure provides small molecule drugs and pharmaceutical compositions for the treatment and prevention of diseases related to the formation of A?42 oligomers in a subject. It further provides a method of reducing formation of or disrupting A?42 oligomers in a subject, the method comprising the step of administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition.
Abstract: The present invention provides small molecule drugs and pharmaceutical compositions for the treatment and prevention of diseases related to the formation of A?42 oligomers in a subject. It further provides a method of reducing formation of or disrupting A?42 oligomers in a subject, the method comprising the step of administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition.
Abstract: The present invention provides small molecule drugs and pharmaceutical compositions for the treatment and prevention of diseases related to the formation of certain types of oligomers in a subject. More specifically, the drugs and compositions reduce or prevent the formation of oligomers formed from tau protein, TDP-43, Huntingtin's protein and/or alpha-synuclein. It further provides a method of reducing formation of or disrupting TDP-43, alpha-synuclein, Huntingtin's protein and/or tau protein oligomers in a subject, the method comprising the step of administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition.
Abstract: The present invention provides small molecule drugs and pharmaceutical compositions for the treatment and prevention of diseases related to the formation of A?42 oligomers in a subject. It further provides a method of reducing formation of or disrupting A?42 oligomers in a subject, the method comprising the step of administering to the subject in need thereof a therapeutically effective amount of a pharmaceutical composition.